Enhancing mitotane efficacy in adrenocortical carcinoma by calcineurin inhibition with cyclosporine A

Year 2024, Volume: 7 Issue: 4, 395 - 401, 30.07.2024

Armagan Akkuş , Müge Gülcihan Önal , Buket Özkan , Merve Başar

https://doi.org/10.32322/jhsm.1488274

Abstract

Aims: The aim of this study is to determine the effect of calcineurin (CaN) in adrenocortical cancer (ACC) cells, which is a rare but aggressive type of cancer resistant to mitotane therapy. The intracellular calcium signaling pathway is one of the most important mechanisms for cells. The effect of intracellular calcium concentration [(Ca2+i)] on the function of cancer cells is also known. CaN, activated by the binding of calmodulin and Ca2+, is critical in this pathway.
Methods: H295 adrenocortical cancer cells were treated with mitotane, cyclosporine A (CsA), and a combination of both. Cell viability, apoptosis, cell cycle, and gene expression levels of apoptosis-related genes (BCL2, BAX, TP53) were analyzed. Western blotting was used to measure CaN protein levels, and wound healing assays assessed cell migration.
Results: CsA significantly suppressed CaN protein levels in a dose-dependent manner, reducing cell viability and increasing apoptosis in H295 cells. Mitotane alone also suppressed CaN protein, but the combination of mitotane and CsA had a synergistic effect, further decreasing cell viability and increasing apoptosis. The combination treatment led to significant suppression of the BCL2 gene and upregulation of TP53. Cell cycle analysis showed increased arrest in the G0/G1 phase with combination treatment.
Conclusion: Suppression of CaN by CsA enhances the cytotoxic effects of mitotane on ACC cells, suggesting a potential therapeutic strategy to improve ACC treatment outcomes. This study highlights the importance of targeting intracellular calcium signaling pathways to overcome resistance and enhance the efficacy of existing cancer therapies.

Keywords

Adrenocortical carcinoma, calcineurin, cyclosporine A, intracellular calcium signaling, mitotane

References

• Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282-326. doi:10.1210/er.2013-1029
• Creemers SG, van Koetsveld PM, de Herder WW, et al. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. Endocr Relat Cancer. 2019. doi:10.1530/ERC-18-0500
• Karwacka I, Obołończyk Ł, Kaniuka-Jakubowska S, Sworczak K. The role of immunotherapy in the treatment of adrenocortical carcinoma. biomedicines. 2021;9(2):1-12. doi:10.3390/BIOMEDICINES9020098
• Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-G46. doi:10.1530/EJE-18-0608
• Creemers SG, Hofland LJ, Korpershoek E, et al. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. Endocr Relat Cancer. 2016;23(1):R43-R69. doi:10. 1530/ERC-15-0452
• Kerkhofs TMA, Ettaieb MHT, Hermsen IGC, Haak HR. Developing treatment for adrenocortical carcinoma. Endocr Relat Cancer. 2015;22(6):R325-R338. doi:10.1530/ERC-15-0318
• Poli G, Guasti D, Rapizzi E, et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer. 2013;20(4):537-550. doi:10.1530/ERC-13-0150
• Corso CR, Acco A, Bach C, Bonatto SJR, de Figueiredo BC, de Souza LM. Pharmacological profile and effects of mitotane in adrenocortical carcinoma. Br J Clin Pharmacol. 2021;87(7):2698-2710. doi:10.1111/BCP.14721
• Creamer TP. Calcineurin. Cell Commun Signal. 2020;28;18(1):137. doi: 10.1186/s12964-020-00636-4
• Berber M, Leng S, Beuschlein F, Breault DT, Loffing J, Ribas DP. Calcineurin-NFATc4 pathway is activated upon K+-stimulation of adrenal aldosterone production. J Endocr Soc. 2021;5(Suppl 1):A805. doi:10.1210/JENDSO/BVAB048.1638
• Chen L, Song M, Yao C. Calcineurin in development and disease. Genes Dis. 2022;9(4):915-927. doi:10.1016/j.gendis.2021.03.002
• Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant. 2012;2012:1-7. doi:10.1155/2012/230386
• Adithan A, John Peter JS, Hossain MA, et al. Biological effects of cyclosporin A on CD3-CD161+ and CD3+CD161+ lymphocytes. Mol Cell Biochem. 2019;458(1-2):159-169. doi: 10.1007/s11010-019-03539-2
• Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O. Lessons to learn from low-dose cyclosporin-A: a new approach for unexpected clinical applications. Front Immunol. 2019;10:588. doi:10.3389/FIMMU.2019.00588
• Devaux CA, Melenotte C, Piercecchi-Marti M-D, Delteil C, Raoult D. Cyclosporin A: a repurposable drug in the treatment of COVID-19? Front Med. 2021;8:663708. doi: 10.3389/fmed. 2021.663708
• Caner A, Onal MG, Bitgen N, Sezer G. The effect of cyclosporine A on proteins controlling intracellular calcium concentration in breast cancer cells. J Membr Biol. 2021:1-7. doi:10.1007/S00232-021-00201-1
• Cosentini D, Grisanti S, Volta AD, et al. Immunotherapy failure in adrenocortical cancer: where next? Endocr Connect. 2018; 7(12):E5. doi:10.1530/EC-18-0398
• Spät A, Hunyady L, Szanda G. Signaling interactions in the adrenal cortex. Front Endocrinol (Lausanne). 2016;7:17. doi:10. 3389/fendo.2016.00017
• Xing Y, Lerario AM, Rainey W, Hammer GD. Development of adrenal cortex zonation. Endocrinol Metab Clin North Am. 2015;44(2):243-274. doi:10.1016/j.ecl.2015.02.001
• Hescot S, Amazit L, Lhomme M, et al. Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches. Oncotarget. 2017;8(66):109924-109940. doi:10.18632/ONCOTARGET.18968
• Boulate G, Amazit L, Naman A, et al. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. Int J Oncol. 2019;54(6):2149-2156. doi:10.3892/IJO.2019.4770/HTML
• Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2-3):119-125. doi:10.1016/S0162-3109(00)00192-2
• Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology. 2003;185(3):229-240.
• Kim HS, Choi S Il, Jeung EB, Yoo YM. Cyclosporine A induces apoptotic and autophagic cell death in rat pituitary GH3 cells. PLoS One. 2014;9(10):108981. doi:10.1371/JOURNAL.PONE. 0108981
• Sato M, Tsujino I, Fukunaga M, et al. Cyclosporine A induces apoptosis of human lung adenocarcinoma cells via caspase-dependent pathway. Anticancer Res. 2011;31(6):2129-2134.
• Roy MK, Takenaka M, Kobori M, Nakahara K, Isobe S, Tsushida T. Apoptosis, necrosis and cell proliferation-inhibition by cyclosporine A in U937 cells (a human monocytic cell line). Pharmacol Res. 2006;53(3):293-302. doi:10.1016/J.PHRS.2005. 12.007
• Pereira SS, Monteiro MP, Antonini SR, Pignatelli D. Apoptosis regulation in adrenocortical carcinoma. Endocr Connect. 2019; 8(5):R91-R104. doi:10.1530/ec-19-0114
• López-Flores R, Bojalil R, Benítez JC, et al. Consecutive low doses of cyclosporine A induce pro-inflammatory cytokines and accelerate allograft skin rejection. Molecules. 2011;16(5):3969-3984. doi:10.3390/molecules16053969